Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  Mesoblast limited    MSB   AU000000MSB8

MESOBLAST LIMITED (MSB)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Securities Exc…
06/18/2018 06/19/2018 06/20/2018 06/21/2018 06/22/2018 Date
1.515(c) 1.47(c) 1.475(c) 1.565(c) 1.55 Last
281 342 1 065 848 416 605 2 449 627 1 556 495 Volume
-0.33% -2.97% +0.34% +6.10% -0.96% Change
More quotes
Financials (AUD)
Sales 2018 67,2 M
EBIT 2018 -51,0 M
Net income 2018 -101 M
Debt 2018 -
Yield 2018 -
Sales 2019 37,0 M
EBIT 2019 -77,2 M
Net income 2019 -61,6 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 10,9x
Capi. / Sales2019 19,7x
Capitalization 729 M
More Financials
Company
Mesoblast Ltd. engages in the research, development, and market of pharmaceutical products.Its medicines target the cardiovascular conditions, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases.The company was founded by Itescu Silviu on June 8, 2004 and... 
More about the company
Surperformance© ratings of Mesoblast limited
Trading Rating : - Investor Rating :
More Ratings
Latest news on MESOBLAST LIMITED
06/21Key Day 100 Survival Outcomes of Phase 3 Trial for Acute Graft Versus Host Di..
GL
06/19U.S. Healthcare Leader Joseph R. Swedish Joins Mesoblast Board
GL
05/31Financial Results and Operational Highlights for the Third Quarter Ended Marc..
GL
05/31Mesoblast Appoints New Chief Financial Officer
GL
05/29Mesoblast Financial Results Webcast for Quarter Ended March 31, 2018
GL
05/29Mesoblast Partners With Cartherics to Develop ’off-the-shelf’ Cel..
GL
05/15MESOBLAST LIMITED : - MSB P3 Results for GVHD Presented At ISCT Meeting
AQ
05/08Mesoblast Phase 3 Trial Results for Acute Graft Versus Host Disease Presented..
GL
05/01Mesoblast Cell Therapies Featured at Vatican International Healthcare Confere..
GL
04/20MESOBLAST LIMITED : Wired News - Mesoblast Announced Updated Data from Phase-3 a..
AC
More news
Sector news : Biotechnology & Medical Research - NEC
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
06/21$MESO (+14.6% pre) Mesoblast's remestemcel-L shows 75% survival rate in child..
2
06/21H.C. Wainwright Reiterates Buy on Mesoblast $MESO Following 100-Day GvHD Data.. 
06/21Mesoblast's remestemcel-L shows 75% survival rate in children with severe for.. 
06/21Cantor Fitzgerald Sticks to Their Buy Rating for Mesoblast Ltd $MESO  
06/19U.S. Healthcare Leader Joseph R. Swedish Joins Mesoblast Board  
More tweets
Qtime:99
News from SeekingAlpha
06/22MESOBLAST : Pushing The Cell Therapy Treatment For An Unmet Medical Need For Chi.. 
06/21Incyte's Jakafi successful in mid-stage study in severe form of GvHD 
06/21Mesoblast's remestemcel-L shows 75% survival rate in children with severe for.. 
06/07HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (06/07/2018) 
05/31Mesoblast Ltd. 2018 Q3 - Results - Earnings Call Slides 
Chart MESOBLAST LIMITED
Duration : Period :
Mesoblast limited Technical Analysis Chart | MSB | AU000000MSB8 | 4-Traders
Technical analysis trends MESOBLAST LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 3,75  AUD
Spread / Average Target 142%
EPS Revisions
Managers
NameTitle
Silviu Itescu Chief Executive Officer, MD & Executive Director
Brian Jamieson Non-Executive Chairman
Joshua Muntner Chief Financial Officer
Donna L. Skerrett Chief Medical Officer
Paul Simmons Head-Research & New Product Development
Sector and Competitors
1st jan.Capitalization (M$)
MESOBLAST LIMITED7.19%542
CELLTRION, INC.--.--%33 064
IQVIA HOLDINGS INC6.98%21 789
LONZA GROUP2.35%20 356
INCYTE CORPORATION-22.94%15 565
ALNYLAM PHARMACEUTICALS, INC.-17.65%10 581